November 23, 2016 - By Pete Kolinski · 0 Comments
The stock of Alcobra Limited Ord (NASDAQ:ADHD) registered a decrease of 2.21% in short interest. ADHD’s total short interest was 1.59M shares in November as published by FINRA. Its down 2.21% from 1.63 million shares, reported previously. With 316,700 shares average volume, it will take short sellers 5 days to cover their ADHD’s short positions. The short interest to Alcobra Limited Ord’s float is 12.63%. The stock last traded at $1.92 per share. It is down 57.05% since April 21, 2016 and is downtrending. It has underperformed by 62.38% the S&P500.
Alcobra Ltd is an Israel-based Biopharmaceutical company. The company has a market cap of $51.06 million. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder , a common and morbid neuropsychiatric condition in children and adults. It currently has negative earnings. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Out of 7 analysts covering Alcobra (NASDAQ:ADHD), 3 rate it a “Buy”, 1 “Sell”, while 3 “Hold”. This means 43% are positive. Alcobra has been the topic of 13 analyst reports since August 9, 2015 according to StockzIntelligence Inc. As per Friday, October 28, the company rating was downgraded by Barclays Capital. As per Sunday, August 9, the company rating was maintained by WBB Securities. The stock of Alcobra Ltd (NASDAQ:ADHD) earned “Buy” rating by TH Capital on Friday, August 14. The stock of Alcobra Ltd (NASDAQ:ADHD) has “Hold” rating given on Monday, August 17 by Zacks. The rating was downgraded by Cantor Fitzgerald on Thursday, September 29 to “Hold”. The firm earned “Buy” rating on Tuesday, June 21 by Roth Capital. The rating was initiated by Barclays Capital with “Equal-Weight” on Monday, August 1. The firm has “Buy” rating given on Thursday, February 18 by Jefferies. The stock has “Perform” rating given by Oppenheimer on Thursday, September 29. As per Monday, January 25, the company rating was initiated by Oppenheimer.
More news for Alcobra Ltd (NASDAQ:ADHD) were recently published by: Quotes.Wsj.com, which released: “Alcobra Ltd. ADHD (US: Nasdaq)” on May 18, 2013. Marketwatch.com‘s article titled: “Alcobra upgraded to hold from sell at WBB Securities” and published on June 27, 2013 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Pete Kolinski